• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infection >Successful treatment of pulmonary invasive aspergillosis with voriconazole in patients who failed conventional therapy.
【24h】

Successful treatment of pulmonary invasive aspergillosis with voriconazole in patients who failed conventional therapy.

机译：在常规治疗失败的患者中，使用伏立康唑成功治疗了肺部侵袭性曲霉病。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The incidence of fungal infections, including those due to Aspergillosis species has continued to increase in recent years. Invasive aspergillosis remains an important cause of morbidity and mortality, despite therapeutics interventions. PATIENTS AND METHODS: We reported five cases of invasive pulmonary aspergillosis treated with voriconazole failing to respond to conventional treatments. RESULTS: The clinical and radiological resolution of pulmonary aspergillosis reported in these cases following therapy with voriconazole is remarkable, considering the infections had proved refractory to standard antifungal therapies. Long-term therapy (in two cases > or = 1 year, in one case 6 months) was very well tolerated by patients who were unable to tolerate other antifungal agents. CONCLUSION: Therapy with voriconazole offers a new therapeutic option for otherwise difficult-to-treat infections and the potential to significantly improve the management of Aspergillosis infections.
机译：背景：近年来，真菌感染的发生率（包括曲霉菌引起的感染）持续增加。尽管有治疗干预，但侵袭性曲霉病仍然是发病率和死亡率的重要原因。患者和方法：我们报告了伏立康唑治疗的5例侵袭性肺曲霉病对常规治疗无效。结果：考虑到感染已证明对标准的抗真菌治疗是难治的，因此在伏立康唑治疗后这些病例中报告的肺曲霉病的临床和放射学缓解显着。不能耐受其他抗真菌药物的患者对长期治疗（在≥1例的两个病例中，≥1年，在6个月中的一个病例中）具有很好的耐受性。结论：伏立康唑疗法为原本难以治疗的感染提供了新的治疗选择，并具有显着改善曲霉菌感染管理的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号